Drug intelligence / Profile preview

Apicort

Development stage: Unknown
Lead developer: Amman Pharmaceutical Industries
Modality: Small Molecules
Administration: Ophthalmic

Overview

Apicort is an ophthalmic corticosteroid developed and marketed by Amman Pharmaceutical Industries. Its active ingredient is prednisolone acetate, a synthetic glucocorticoid receptor agonist. It is formulated as eye drops in two concentrations: 0.12% and 1% (Apicort Forte). The drug is indicated for the treatment of steroid-responsive inflammation and mild to moderate non-infectious allergic disorders affecting the eyelid, conjunctiva, cornea, and anterior segment of the eye. It provides relief for inflammatory ocular conditions such as conjunctivitis.

Brand names: ApicortApicort Forte
Other names: prednisolone acetate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Apicort.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apicort.

Explore the full profile